Tesaro Inc., has just announced that it has received the approval of Varuby® (oral rolapitant tablets) by European Commission
A source said via Thomson Reuters Eikon that commercial launches to begin on a country-by-country basis in Europe by end of Q2.
Tesaro is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our business, and we are committed to being a trusted partner to the cancer community.